Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
BeOne Medicines
MacroGenics
Incyte Corporation
Janux Therapeutics
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
University of Virginia
Incyte Corporation
Theratechnologies
Sotio Biotech Inc.
Carisma Therapeutics Inc
AstraZeneca
Xencor, Inc.
HiberCell, Inc.
Zhejiang University
University of Florida
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Genocea Biosciences, Inc.
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Celgene
MedImmune LLC
University of Wisconsin, Madison
AbbVie
Pfizer
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Santa Maria Biotherapeutics
University of Southern California
Northwestern University
Yale University
EMD Serono
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Duke University
GlaxoSmithKline
Alaunos Therapeutics
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Case Comprehensive Cancer Center